Background & Objectives
Multiple Sclerosis (MS) is the second most common cause of neurological disability and highest per capita costs among all other neurological disorders [1]. Even though France has the lowest prevalence rates among other north European countries (94.7 per 100,000) [2], in 2009 the total annual cost per patient was estimated at €44,400, translated in an estimated total cost of €1.3 billion per year for MS in France [3].

Conclusions & Future directions
MS poses a significant cost burden for the French society, with medication and indirect costs representing 88% of total average costs and substantial unmet needs being reported in the clinical management and social care currently received by MS patients in France.

Figure 2. Preferred sources of information for individuals with MS in France

4% • MS websites
16% • MS magazines or publications
48% • Social media
6% • Health websites
22% • Online forums
13% • Online support groups
13% • Group support meetings
28% • Family and friends with experience of MS
10% • My doctor
14% • I have not looked for information

Table 1. Sample HRQoL characteristics [mean (SD)] and statistical significance (p) of differences between type of MS groups.

Conclusions & Future directions

MS poses a significant cost burden for the French society, with medication and indirect costs representing 88% of total average costs and substantial unmet needs being reported in the clinical management and social care currently received by MS patients in France.

The absence of long-term, real world data about the cost-effectiveness of receiving DMT earlier in the course of the disease, when to initiate treatment and which DMT to use are still to be determined.

Acknowledgments

We are grateful to the European MS Platform (EMSP), ARSEP – French MS Research Society and Ligue Sclérose qui facilitated data collection and also, to all the Anonymous respondents who provided the information and insights captured in the study. Finally, we thank F. Hoffmann-La Roche that provided the sponsorship to carry out this research.

References

This research consists part of “The International Multiple Sclerosis Study (IMPRESS) which is available online at http://www.lesc.org.uk/healthcareResearch/ProjectResearch/LESE/HealthcareResearch/IMPRESS-Report-March-2010.pdf

CONTACT US
Olfan Efthymiadou (MS), Medical Technology Research Group, LSE Health, London School of Economics, Houghton Street, London, WC2A 2AE, UK
+44(0)207 849 4991, A.Efthymiadou@lse.ac.uk

Figure 1. Average annual cost (€ 2014-15) per patient across all sample and type of MS in France

<table>
<thead>
<tr>
<th>All sample (n=92)</th>
<th>RRMS (n=52)</th>
<th>SPMS (n=8)</th>
<th>PPMS (n=12)</th>
<th>Unknown type (n=25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EQ-5D-5L Utility</td>
<td>0.48 (0.28)*</td>
<td>0.55 (0.24)</td>
<td>0.23 (0.32)</td>
<td>0.32 (0.37)</td>
</tr>
<tr>
<td>Utility loss</td>
<td>0.34 (0.28)*</td>
<td>0.27 (0.24)</td>
<td>0.6 (0.32)</td>
<td>0.51 (0.37)</td>
</tr>
<tr>
<td>EQ-5D-5L VAS</td>
<td>60.5 (22)</td>
<td>65.2 (21)</td>
<td>46.25 (22)</td>
<td>50.9 (21.3)</td>
</tr>
<tr>
<td>Barthel index</td>
<td>17.5 (3.3)*</td>
<td>18.6 (1.9)</td>
<td>14.3 (4.5)</td>
<td>14.4 (4.6)</td>
</tr>
<tr>
<td>Treatment satisfaction</td>
<td>7.4 (2.3)</td>
<td>7.6 (2.2)</td>
<td>7.7 (3.0)</td>
<td>6.1 (2.8)</td>
</tr>
</tbody>
</table>

*p<0.001